Group 1: Overall Strategy and Market Trends - The report highlights a dual-driven strategy where technology and cyclical sectors are rebalancing, with opportunities in the chemical industry emerging under the "anti-involution" trend [7][8] - The A-share market is experiencing accelerated capacity clearance, indicating a turning point for cyclical industries, particularly in chemicals, which show significant advantages over traditional sectors like steel and coal [8][9] - The chemical industry is expected to enter a new prosperity cycle driven by supply-demand recovery and anti-involution policies, with a notable decrease in capital expenditure and a resilient export market [9][10] Group 2: Industry-Specific Insights - The military industry is currently facing high valuations, with a PE-TTM of 67.34, indicating a slight decrease from previous weeks, while geopolitical uncertainties are expected to accelerate military orders [13][14] - The real estate sector shows signs of stabilization, with new home transaction areas increasing month-on-month, supported by government policies aimed at boosting investment and consumption [17][21] - The consumer services sector, particularly in tourism and dining, is witnessing a recovery, with companies like Ctrip and Haidilao reporting strong performance and expansion plans [24][25] Group 3: Company-Specific Developments - Lenovo Group is benefiting from the Windows 11 upgrade cycle, with a projected non-GAAP net profit growth of 21.8% for FY2026, reflecting strong supply chain resilience [29][30] - NetEase is expected to see growth driven by overseas gaming expansion and new game launches, with a projected net profit increase of 31.8% in Q3 2025 [34][35] - Dawi Technology is focusing on AI data centers, with plans to enhance its competitive edge through strategic partnerships and infrastructure development [38][39]

Core Insights - The Hong Kong innovative drug sector is experiencing a rebound, with the Hong Kong Stock Connect innovative drug ETF (520880) rising by 1.66% at one point [1] - Major stocks such as Sanofi, Kelun-Biotech, and Hengrui Medicine saw increases of over 4%, while stocks like China Resources Pharmaceutical and Fuxing Pharmaceutical faced adjustments [1] Industry Trends - The innovative drug industry is shifting from a quantity-driven approach to a quality-driven one, entering a phase where product efficacy is paramount [3] - There is a growing focus on differentiated and internationalized pipelines, with an emphasis on products that can generate profits [3] - Oral peptide drugs, such as PCSK9 inhibitors and IL-23 antagonists, are showing promising clinical data and have the potential to reshape treatment paradigms [3] Market Dynamics - Chinese innovative pharmaceutical companies are deeply involved in global drug development, with the number of clinical trials ranking first worldwide, particularly in cell therapy, ADCs, and bispecific antibodies [3] - By 2024, it is expected that 38% of globally approved new drugs will have their first launch in China, highlighting the country's growing importance in the pharmaceutical landscape [3] - The upcoming expiration of patents for multinational corporations (MNCs) is creating opportunities for Chinese assets, which are becoming significant sources for important projects [3] ETF Performance - The Hong Kong Stock Connect innovative drug ETF (520880) and its linked funds are passively tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which includes top-weighted stocks like BeiGene, China Biologic Products, and Innovent Biologics [3]

Core Viewpoint - In 2024, Kangzhe Pharmaceutical's core cardiovascular business faced revenue and profit declines due to unsuccessful bidding in centralized procurement, prompting its subsidiary Dermavon to apply for an IPO on the Hong Kong Stock Exchange despite ongoing losses in its skin care segment [3][4]. Group 1: Company Overview - Dermavon, established in 2020 and spun off from Kangzhe in 2021, focuses on skin prescription drugs and skin care products, holding three marketed drugs and a developing skin care brand [4][6]. - Kangzhe Pharmaceutical's revenue in 2024 was 7.469 billion yuan, a decrease of 6.8% year-on-year, with net profit dropping by 32.3% to 1.613 billion yuan [4]. Group 2: Financial Performance - Dermavon reported revenue growth from 384 million yuan in 2022 to 618 million yuan in 2024, but net losses increased from 55.17 million yuan to 106 million yuan during the same period [8][9]. - Sales expenses for Dermavon rose from 246 million yuan in 2022 to 388 million yuan in 2024, consistently accounting for around 60% of revenue [9][10]. Group 3: Market Position and Challenges - Dermavon's core product, Yilvqu (for psoriasis), lacks price competitiveness compared to established competitors, which impacts market penetration and necessitates high marketing expenditures [11][12]. - The skin care segment, particularly the He Ling series targeting sensitive skin, faces intense competition from established brands like Winona, which reported revenue of 4.91 billion yuan in 2024, significantly overshadowing Dermavon's performance [13][14]. Group 4: Future Outlook and Strategic Goals - Dermavon aims for a compound annual growth rate of over 50% over the next five years, targeting sales exceeding 10 billion yuan by 2029, although achieving this goal poses significant challenges given the current market dynamics [14][18]. - The company's reliance on Kangzhe for resources and sales channels raises concerns about its independence and long-term viability, as it struggles to establish a self-sustaining business model [16][17].

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, prompting a leadership change and strategic reassessment [4][6][20]. Company Overview - Aimeike's stock price peaked at 1331 yuan in February 2021, with a market capitalization exceeding 150 billion yuan, earning it the nickname "the Moutai of women" [4]. - The company has seen a dramatic decline in performance, with a 21.27% drop in revenue and a 34.61% drop in net profit in Q3 2025 compared to the previous year [6][8]. Financial Performance - Aimeike's financial performance over the past five years shows a significant decline, with 2025 projections indicating a drop in revenue and net profit by over 20% [9][13]. - The company's revenue and net profit for 2025 are expected to be 18.65 billion yuan and 10.93 billion yuan, respectively, marking a substantial decrease from previous years [9][13]. Product Development and Market Position - Aimeike's growth was initially driven by innovative products like the "Hi Body" and "Moisturizing Angel," which captured significant market share [10][11]. - However, competition has intensified, particularly in the high-end segment, leading to a dilution of the unique advantages of core products [12][14]. Strategic Response - In response to market challenges, Aimeike is diversifying its product offerings and has initiated a shift towards biopharmaceuticals and chemical drugs [15]. - The company has also pursued acquisitions, such as the purchase of a majority stake in REGEN, to enhance its product portfolio and market competitiveness [17][18]. Agency Dispute - Aimeike is embroiled in a significant dispute over the agency rights for its product AestheFill, which has implications for its market strategy and financial performance [18][19]. - The resolution of this dispute is critical for Aimeike's management to demonstrate their capability to navigate challenges and restore growth [20].

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, leading to a critical management transition [1][2]. Group 1: Company Performance - In the first half of 2025, Aimeike reported its first negative growth, with Q3 revenue at 566 million yuan and net profit at 304 million yuan, down 21.27% and 34.61% year-on-year, respectively [2]. - The company's market capitalization has dropped to approximately 45 billion yuan, a decline of over 100 billion yuan from its peak [2]. - The core products, including the solution-based injection products and gel-based injection products, have seen revenue declines of 23.79% and 23.99% respectively in the first half of 2025 [6]. Group 2: Management Changes - The recent board reshuffle saw Jian Jun re-elected as chairman, while the resignation of the board secretary, Jian Yong, and the appointment of Li Dongmei as the new secretary raised market interest [1][2]. - The new management faces the challenge of addressing the company's declining performance and resolving the ongoing agency disputes [2][12]. Group 3: Product Development and Market Dynamics - Aimeike's growth was initially driven by innovative products, such as the first domestically developed hyaluronic acid injection, which captured significant market share [3][4]. - The company has expanded its product matrix, with gel-based products showing substantial growth, achieving revenue of 1.158 billion yuan in 2023, a year-on-year increase of 81.43% [5]. - However, increased competition in the medical beauty sector has diluted the uniqueness of Aimeike's core products, leading to a more challenging market environment [6][7]. Group 4: Strategic Initiatives - Aimeike is pursuing diversification in its product offerings, including the launch of new products like the medical-grade polyethylene glycol gel [8]. - The company has also engaged in strategic acquisitions, such as the 190 million USD purchase of a majority stake in REGEN, to enhance its product portfolio and market competitiveness [9][10]. Group 5: Agency Disputes - Aimeike is embroiled in a significant agency dispute over the AestheFill product, which has implications for its market strategy and financial performance [10][11]. - The conflict escalated with the termination of the exclusive distribution agreement by Jiangsu Wuzhong, leading to potential legal ramifications and financial claims [11][12]. - The resolution of this dispute is critical for Aimeike's management to demonstrate its capability to navigate challenges and restore growth [13].

Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, prompting a recent board reshuffle to address these issues [1][2][6]. Company Overview - Aimeike's actual controller, Jian Jun, was re-elected as chairman, while the management team remains stable, with Li Dongmei being promoted to a key role amid the company's current challenges [1][2]. - The company has seen a drastic decline in stock price and market capitalization, dropping from a peak of over 150 billion yuan to around 45 billion yuan [2][6]. Financial Performance - In the first half of 2025, Aimeike reported a revenue of 5.66 billion yuan and a net profit of 3.04 billion yuan, marking declines of 21.27% and 34.61% year-on-year, respectively [2][6]. - The company experienced its first negative growth in 2025, with revenue and net profit both declining over 20% [6][7]. Product Development and Market Position - Aimeike's growth has been closely tied to its innovative product development, with key products like "HiTi" and "Luhua Tianzi" driving significant revenue [3][5]. - The company has expanded its product matrix, with "HiTi" achieving a revenue share increase from 15.34% in 2017 to 43.5% in 2019 [4]. Competitive Landscape - The medical beauty industry is undergoing rapid changes, with increased competition leading to a dilution of Aimeike's product advantages, particularly for "HiTi" and "Luhua Tianzi" [7][8]. - New entrants in the market have intensified competition, with the number of approved "童颜针" products increasing to seven, further squeezing Aimeike's growth potential [8][9]. Strategic Initiatives - Aimeike is diversifying its product offerings, including the launch of new products like "Kela" and expanding into biopharmaceuticals and chemical drugs [9][10]. - The company has also pursued acquisitions, such as the purchase of a majority stake in REGEN, to enhance its product portfolio and market competitiveness [10][11]. Legal and Regulatory Challenges - Aimeike is embroiled in a significant dispute over the agency rights for its product "AestheFill," which could impact its market performance and brand partnerships [11][12]. - The ongoing arbitration with Jiangsu Wuzhong over the exclusive distribution rights of "AestheFill" highlights the complexities of brand ownership and distribution in the medical beauty sector [12][15].

Core Viewpoint - The announcement by Sihuan Pharmaceutical (00460.HK) regarding the proposal for full circulation of H-shares for Xuan Bamboo Biotechnology, which involves converting 357,245,794 unlisted shares into H-shares, representing approximately 68.9733% of the total issued shares as of November 14, 2025 [1] Group 1 - Xuan Bamboo Biotechnology submitted a filing application to the China Securities Regulatory Commission on November 17, 2025, for the conversion of shares [1] - The conversion will be on a one-to-one basis for six shareholders [1] - As of the announcement date, Xuan Bamboo has not yet applied for the listing and trading of these H-shares on the Hong Kong Stock Exchange [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 軒竹生物建議實施H股全流通 此 乃 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」）作 出 的 自 願 公 告。 茲 提 述 本 公 司 之 附 屬 公 司 軒 竹 生 物 科 技 股 份 有 限 公 司（「軒竹生物」，於 二 零 二 五 年 十 月 十 五 日 在 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）主 板 上 市，股 份 代 號：2575） 日 期 為 二 零 二 五 年 十 一 月 十 四 日 及 二 零 二 五 年 十 一 月 十 七 日 的 公 告（「該等公 告」），內 容 有 關 經 軒 竹 生 物 董 事 會 考 慮 及 批 准 ...

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The share buybacks in the second half were divided into two phases: the first from September 15 to September 24, and the second from October 27 to November 5 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with a net profit of CNY 305 million, a decrease of 10.63% [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Performance - The medical aesthetics segment generated CNY 575 million, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [5]. - The epidermal growth factor products saw revenue of CNY 92.38 million, reflecting a growth of 13.73% [5]. Market Position and Valuation - Haohai's current PE (TTM) ratio is 14.82, below the industry average of 20, indicating potential undervaluation [3]. - Despite the stock price decline, the company maintains a net asset value of HKD 26.93 per share, providing an arbitrage opportunity for investors [7]. - Since August 20, 2023, the proportion of shares held by Hong Kong Stock Connect investors has increased from 30.35% to 35.78% [7]. Strategic Focus on Botulinum Toxin - The company has invested USD 31 million in Eirion to develop various botulinum toxin products, aiming to capture a share of the growing market [9]. - The medical aesthetics injection market is dominated by hyaluronic acid and botulinum toxin, which together account for 65% of the market [10]. - The domestic penetration rate for botulinum toxin is significantly lower than in mature markets, suggesting substantial growth potential [12]. Future Outlook - Despite current performance challenges, the company's ongoing development in the botulinum toxin sector may provide a pathway for recovery [14]. - The collaboration with Eirion is expected to yield new products that could enhance market presence and profitability in the future [14].

Summary of the Conference Call for Sihuan Pharmaceutical Industry Overview - Sihuan Pharmaceutical has been expanding into the medical aesthetics sector since 2014, starting with the Korean botulinum toxin product, Letibotulinum, which was approved for sale in China in 2020. The revenue from this product is expected to reach nearly 1 billion yuan by 2025, accounting for 80% of the medical aesthetics business [2][3][4]. Key Points and Arguments - **Revenue Growth**: In the first half of the year, Sihuan Pharmaceutical achieved revenue of 585 million yuan, representing a year-on-year growth of 81%. The company anticipates a full-year growth of no less than 50% [2][3]. - **Product Launches**: The company has introduced self-developed products such as the "Youthful Needle," "Girl Needle," and "Water Light Energy Serum," which are expected to contribute significantly to revenue [2][3]. - **Market Coverage**: Sihuan Pharmaceutical has established a strong market presence, covering over 7,000 medical aesthetic institutions and achieving 100% coverage with 500 leading institutions. Additionally, strategic cooperation agreements have been signed with 1,400 key institutions [2][3]. - **Production Capacity**: The company operates three production bases to ensure product quality and currently sells six major products, including botulinum toxin, hyaluronic acid, and self-developed products [2][4]. - **Research and Development**: Sihuan Pharmaceutical has built five major R&D platforms, covering international innovative materials and regenerative materials, with over 60 medical aesthetic products in its portfolio. The company conducts hundreds of medical training sessions and market activities annually to enhance academic promotion [2][4]. - **Financial Position**: The company has approximately 3.9 billion yuan in cash, indicating strong financial resources to support future growth [2][4]. Competitive Landscape - **Botulinum Toxin Market**: Letibotulinum currently accounts for about 80% of Sihuan Pharmaceutical's medical aesthetics revenue. As new self-developed products are launched, this proportion is expected to decrease. Letibotulinum is the first Korean botulinum toxin brand approved in China and has maintained a leading position due to its suitability for Asian skin [3][4]. - **Market Penetration**: The domestic botulinum toxin market has low penetration rates, but the company believes that increased competition will drive growth in market penetration. The safety and affordability of botulinum toxin are expected to attract more consumers [4][5]. Product Differentiation - **Hyaluronic Acid Product**: The company’s hyaluronic acid product, "Bohuanrun," utilizes HEXALINK™ unidirectional cross-linking technology, enhancing its resistance to pressure and deformation, with a stable shaping effect lasting up to one year. It is positioned competitively in a crowded market [6]. - **Comprehensive Product Line**: Sihuan Pharmaceutical offers a wide range of products, including injectables, fillers, water light needles, collagen, and silk protein, establishing a comprehensive product layout [7]. Unique Selling Proposition - **CDK 4/6 Inhibitor**: The company’s CDK 4/6 inhibitor is the first and only approved drug for monotherapy in the domestic market, with low toxicity and broad indications. The company plans to leverage its unique characteristics and clinical performance to maximize market potential [8][9]. Future Outlook - **Revenue Targets**: Sihuan Pharmaceutical aims to achieve over 1 billion yuan in revenue from existing products and 200 million yuan from new products by 2025, with total revenue reaching 1.2 billion yuan. The company expects to maintain an annual growth rate of no less than 50% over the next two to three years [2][4][12].